MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: Results from the AML05 multicenter trial

Blood

Volumn 121, Issue 20, 2013, Pages 4056-4062

  Zhu, Hong Hu ^a   Zhang, Xiao Hui ^a   Qin, Ya Zhen ^a   Liu, Dai Hong ^a   Jiang, Hao ^a   Chen, Huan ^a   Jiang, Qian ^a   Xu, Lan Ping ^a   Lu, Jin ^a   Han, Wei ^a   Bao, Li ^a   Wang, Yu ^a   Chen, Yu Hong ^a   Wang, Jing Zhi ^a   Wang, Feng Rong ^a   Lai, Yue Yun ^a   Chai, Jun Yue ^b   Wang, Li Ru ^c   Liu, Yan Rong ^a   Liu, Kai Yan ^a   Jiang, Bin ^a   Huang, Xiao Jun ^a,d   more..

^a PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^b Beijing no 6 Hospital   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

^d Tsinghua University   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYTARABINE; DAUNORUBICIN; HOMOHARRINGTONINE; IDARUBICIN; MITOXANTRONE; TRANSCRIPTION FACTOR RUNX1;

ACUTE MYELOID LEUKEMIA; ADOLESCENT; ADULT; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DISEASE FREE SURVIVAL; FEMALE; GRAFT VERSUS HOST REACTION; HIGH RISK PATIENT; HUMAN; INDUCTION CHEMOTHERAPY; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE; ACUTE GRANULOCYTIC LEUKEMIA; CHROMOSOME 21; CHROMOSOME 8; CONSOLIDATION CHEMOTHERAPY; GENE TRANSLOCATION; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MINIMAL RESIDUAL DISEASE; MORTALITY; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; PROGNOSIS; REMISSION; RISK ASSESSMENT; SURVIVAL;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOMES, HUMAN, PAIR 21; CHROMOSOMES, HUMAN, PAIR 8; COMBINED MODALITY THERAPY; CONSOLIDATION CHEMOTHERAPY; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; NEOPLASM, RESIDUAL; PROGNOSIS; REMISSION INDUCTION; RISK ASSESSMENT; SURVIVAL ANALYSIS; TRANSLOCATION, GENETIC; YOUNG ADULT;

MLCS; MLOWN;

EID: 84880991962     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-11-468348     Document Type: Article

References (30)

1. Grimwade D, Walker H, Oliver F, et al; The Medical Research Council Adult and Children’s Leukaemia Working Parties. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood. 1998;92(7):2322-2333.
2. Byrd JC, Dodge RK, Carroll A, et al. Patients with t(8;21)(q22;q22) and acute myeloid leukemia have superior failure-free and overall survival when repetitive cycles of high-dose cytarabine are administered. J Clin Oncol. 1999;17(12): 3767-3775.
3. Nguyen S, Leblanc T, Fenaux P, et al. A white blood cell index as the main prognostic factor in t(8;21) acute myeloid leukemia (AML): a survey of 161 cases from the French AML Intergroup. Blood. 2002;99(10): 3517-3523.
4. Schlenk RF, Benner A, Krauter J, et al. Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol. 2004; 22(18):3741-3750.
5. Marcucci G, Mrózek K, Ruppert AS, et al. Prognostic factors and outcome of core binding factor acute myeloid leukemia patients with t(8;21) differ from those of patients with inv(16): a Cancer and Leukemia Group B study. J Clin Oncol. 2005; 23(24):5705-5717.
6. Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. Br J Haematol. 2006;135(2): 165-173.
7. Schlenk RF, Pasquini MC, Pérez WS, et al; CIBMTR Acute Leukemia Working Committee. HLA-identical sibling allogeneic transplants versus chemotherapy in acute myelogenous leukemia with t(8;21) in first complete remission: collaborative study between the German AML Intergroup and CIBMTR. Biol Blood Marrow Transplant. 2008;14(2):187-196.
8. Gorin NC, Labopin M, Frassoni F, et al. Identical outcome after autologous or allogeneic genoidentical hematopoietic stem-cell transplantation in first remission of acute myelocytic leukemia carrying inversion 16 or t(8;21): a retrospective study from the European Cooperative Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26(19): 3183-3188.
9. Kuwatsuka Y, Miyamura K, Suzuki R, et al. Hematopoietic stem cell transplantation for core binding factor acute myeloid leukemia: t(8;21) and inv(16) represent different clinical outcomes. Blood. 2009;113(9):2096-2103.
10. Paschka P, Marcucci G, Ruppert AS, et al; Cancer and Leukemia Group B. Adverse prognostic significance of KIT mutations in adult acute myeloid leukemia with inv(16) and t(8;21): a Cancer and Leukemia Group B Study. J Clin Oncol. 2006;24(24):3904-3911.
11. Cairoli R, Beghini A, Grillo G, et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood. 2006;107(9):3463-3468.
12. Schnittger S, Kohl TM, Haferlach T, Kern W, Hiddemann W, Spiekermann K, Schoch C. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood. 2006;107(5):1791-1799.
13. Buccisano F, Maurillo L, Spagnoli A, et al. Cytogenetic and molecular diagnostic characterization combined to postconsolidation minimal residual disease assessment by flow cytometry improves risk stratification in adult acute myeloid leukemia. Blood. 2010;116(13): 2295-2303.
14. Buccisano F, Maurillo L, Del Principe MI, et al. Prognostic and therapeutic implications of minimal residual disease detection in acute myeloid leukemia. Blood. 2012;119(2):332-341.
15. Alonzo TA, Ho PA, Gerbing RB, et al. Conventional cytogenetics, molecular profiling, and flow cytometric response data allow the creation of a two-tiered risk-group system for risk-based therapy allocation in childhood AML: a report from the Children’s Oncology Group [abstract]. Blood. 2010;116:761a.
16. Campana D, Pui C-H. Detection of minimal residual disease in acute leukemia: methodologic advances and clinical significance. Blood. 1995; 85(6):1416-1434.
17. Campana D. Determination of minimal residual disease in leukaemia patients. Br J Haematol. 2003;121(6):823-838.
18. Rubnitz JE, Inaba H, Dahl G, et al. Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. Lancet Oncol. 2010;11(6): 543-552.
19. Schnittger S, Weisser M, Schoch C, Hiddemann W, Haferlach T, Kern W. New score predicting for prognosis in PML-RARA1, AML1-ETO1, or CBFBMYH111 acute myeloid leukemia based on quantification of fusion transcripts. Blood. 2003; 102(8):2746-2755.
20. Krauter J, Gorlich K, Ottmann O, et al. Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol. 2003;21(23):4413-4422.
21. Leroy H, de Botton S, Grardel-Duflos N, et al. Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia. 2005; 19(3):367-372.
22. Perea G, Lasa A, Aventín A, et al; Grupo Cooperativo para el Estudio y Tratamiento de las Leucemias Agudas y Miel. Prognostic value of minimal residual disease (MRD) in acute myeloid leukemia (AML) with favorable cytogenetics [t(8;21) and inv(16)]. [t(8;21) and inv(16)] Leukemia. 2006;20(1):87-94.
23. Weisser M, Haferlach C, Hiddemann W, Schnittger S. The quality of molecular response to chemotherapy is predictive for the outcome of AML1-ETO-positive AML and is independent of pretreatment risk factors. Leukemia. 2007;21(6): 1177-1182.
24. Lane S, Saal R, Mollee P, et al. A .or51 log rise in RQ-PCR transcript levels defines molecular relapse in core binding factor acute myeloid leukemia and predicts subsequent morphologic relapse. Leuk Lymphoma. 2008;49(3):517-523.
25. Qin YZ, Li JL, Zhu HH, et al. [Detection of common fusion transcript levels in untreated leukemia patients by real-time quantitative RT-PCR technique]. Zhonghua Xue Ye Xue Za Zhi. 2007;28(7):433-437.
26. Döhner H, Estey EH, Amadori S, et al; European LeukemiaNet. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-474.
27. Lu DP, Dong LJ, Wu T, et al. Conditioning including antithymocyte globulin followed by unmanipulated HLA-mismatched/ haploidentical blood and marrow transplantation can achieve comparable outcomes with HLA-identical sibling transplantation. Blood. 2006;107(8): 3065-3073.
28. Anderson JR, Cain KC, Gelber RD. Analysis of survival by tumor response. J Clin Oncol. 1983; 1(11):710-719.
29. Liu Yin JA, O’Brien MA, Hills RK, et al. Minimal residual disease monitoring by RT-qPCR in core-binding factor AML allows risk-stratification and predicts relapse: results of the UK MRC AML-15 trial. Blood. 2012;120(14):2826-2835.
30. Jourdan E, Boissel N, Chevret S, et al. Prospective evaluation of gene mutations and minimal residual disease in patients with core binding factor acute myeloid leukemia. Blood. 2013;121(12):2213-2223.